- Home
- WLYB vs CNTA Comparison
WLYB vs CNTA Comparison
Compare WLYB & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLYB
- CNTA
- Stock Information
- Founded
- WLYB 1807
- CNTA 2020
- Country
- WLYB United States
- CNTA United Kingdom
- Employees
- WLYB N/A
- CNTA N/A
- Industry
- WLYB Books
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- WLYB Consumer Discretionary
- CNTA Health Care
- Exchange
- WLYB Nasdaq
- CNTA Nasdaq
- Market Cap
- WLYB 2.7B
- CNTA 2.2B
- IPO Year
- WLYB N/A
- CNTA 2021
- Fundamental
- Price
- WLYB $51.93
- CNTA $16.00
- Analyst Decision
- WLYB
- CNTA Strong Buy
- Analyst Count
- WLYB 0
- CNTA 7
- Target Price
- WLYB N/A
- CNTA $23.71
- AVG Volume (30 Days)
- WLYB 193.0
- CNTA 463.7K
- Earning Date
- WLYB 12-04-2024
- CNTA 11-12-2024
- Dividend Yield
- WLYB 2.68%
- CNTA N/A
- EPS Growth
- WLYB N/A
- CNTA N/A
- EPS
- WLYB N/A
- CNTA N/A
- Revenue
- WLYB $1,825,783,000.00
- CNTA $6,853,000.00
- Revenue This Year
- WLYB N/A
- CNTA N/A
- Revenue Next Year
- WLYB $1.12
- CNTA N/A
- P/E Ratio
- WLYB N/A
- CNTA N/A
- Revenue Growth
- WLYB N/A
- CNTA N/A
- 52 Week Low
- WLYB $28.35
- CNTA $5.58
- 52 Week High
- WLYB $52.58
- CNTA $18.74
- Technical
- Relative Strength Index (RSI)
- WLYB 69.63
- CNTA 49.07
- Support Level
- WLYB $49.30
- CNTA $15.15
- Resistance Level
- WLYB $52.29
- CNTA $18.74
- Average True Range (ATR)
- WLYB 0.08
- CNTA 0.88
- MACD
- WLYB 0.16
- CNTA 0.10
- Stochastic Oscillator
- WLYB 88.77
- CNTA 35.68
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is a provider of academic journals, books, pre- and post-hire assessments and training, test preparation materials, and online education program management solutions. The company's reportable segments are; Research, Learning, Held for Sale or Sold. The majority of the company's revenue is generated from the Research segment which provides peer-reviewed scientific, technical, and medical (STM) publishing, content platforms, and related services to academic, corporate, and government customers, academic societies, and individual researchers. Geographically, it derives maximum revenue from the United States and the rest from the United Kingdom, China, Japan, Canada, and other countries.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.